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Congenital generalized lipodystrophy (CGL) is an autosomal recessive disease characterized by the
generalized scant of adipose tissue. CGL type 1 is caused by mutations in gene encoding 1-acylglycerol-3-
phosphate O-acyltransferase-2 (AGPAT2). A clinical and molecular genetic investigation was performed in
affected and unaffected members of two families with CGL type 1. The AGPAT2 coding region was
sequenced in index cases of the two families. The presence of the identiﬁed mutations in relevant parents
was tested. We identiﬁed a novel nonsense mutation (c.685G>T, p.Glu229*) and a missense substitution
(c.514G>A, p.Glu172Lys). The unaffected parents in both families were heterozygous carrier of the
relevant mutation. The results expand genotypeephenotype spectrum in CGL1 and will have applica-
tions in prenatal and early diagnosis of the disease. This is the ﬁrst report of Persian families identiﬁed
with AGPAT2 mutations.
 2012 Elsevier Masson SAS. Open access under CC BY license.1. Introduction
Congenital generalized lipodystrophy (CGL) is a rare metabolic
disease, transmitted in an autosomal recessive mode. The world-
wide prevalence of CGL has been estimated at one in 10 million [1].
Interestingly, Rajab et al. reported a signiﬁcantly higher incidence
of one in 25,000 births in Oman [2].
The disease is characterized by a near total loss of adipose tissue
throughout the body from birth, resulting in a marked and gener-
alizedmuscular appearance [3]. The other common clinical features
include muscular hypertrophy, resistance to insulin, hyper-
triglyceridemia, acanthosis nigricans, hyperandrogenism, hep-
atosplenomegaly and acromegaly [4,5]. Studies indicated that CGL
increases the risk of development of type 2 diabetes mellitus and
cardiovascular diseases [6,7]. Mortality in CGL is mainly due to liver,
kidney and heart impairment [8]. Four genes have been identiﬁedfax: þ44 (0)1865 287501.
haghighimd@yahoo.com
work.
nder CC BY license.to cause different types of CGL; AGPAT2 (9q34) [9], BSCL2 (11q13)
[10], CAV1 (7q31.1) [11] and PTRF (17q21.2) [12]. Twomajor forms of
congenital generalized lipodystrophy, CGL1 (caused by AGPAT2
mutations) and CGL2 (due tomutation in BSCL2), account for 95% of
all cases [13]. They have some similar and some distinct clinical
features. For example, lack of metabolically active adipose tissue is
a common ﬁnding in both forms but CGL2 patients lack mechanical
adipose tissue as well [14]. Risk of some conditions such as
cardiomyopathy and mental retardation is increased in patients
affected by CGL2 [3,15].
AGPAT2 encodes an enzyme 1-acyl-glycerol-3-phosphate acyl-
transferase-b, which has a role in the synthesis of triglycerides by
catalyzing the conversion of 1-acylglycerol-3-phosphate (lyso-
phosphatidic acid [16]) to 1,2-diacylglycerol-3-phosphate (phos-
phatidic acid) [17, 18]. AGPAT2 is highly expressed in the adipose
tissue. Mutations that cause deﬁciency of AGPAT2 protein result in
a decrease of triglyceride or phospholipid biosynthesis that can
lead to lipodystrophy [19].
In this study, we investigated clinical features of the ﬁrst fami-
lies with congenital generalized lipodystrophy in Persian pop-
ulation and identiﬁed the disease causing AGPAT2 mutations in
these two unrelated cases.
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2.1. Patients and families
Two Persian families with congenital generalized lipodystrophy
were studied. Written consent for participation in clinical and
molecular investigation was obtained from all members of both
families. All family members underwent a comprehensive physical
examination.
2.2. Molecular analysis
Peripheral blood samples were collected from all participating
familymembers. Genomic DNAwas extracted using Qiagenmini kit
(Qiagen, Hilden, Germany) according to manufacturer’s
instructions.
Direct sequencing of AGPAT2 genewas performed using the DNA
samples of patients from both families. Six exons and ﬂanking
sequence of AGPAT2 gene were ampliﬁed by PCR using gene-
speciﬁc primers described previously [9]. The PCR products were
directly sequenced using standard methods on a Big Dye Termi-
nator Cycler Sequencing Kit v3.1 (Applied Biosystems, Warrington,
UK). The reactions were analyzed on an ABI 3730 (Applied Bio-
systems). Sequences were compared with the published reference
sequence (NM_006412.3) using Mutation Surveyor v3.2 (SoftGe-
netics, State College, PA). The unaffected parents were tested for the
presence of mutations identiﬁed in the probands.
3. Results
3.1. Clinical description
Family 1: The male proband (case1) was admitted to the pedi-
atric surgery department at the age of 2 months because of a mass
in his right groin. He was diagnosed with right inguinal hernia and
operated. He was then referred to the department of pediatric
gastroenterology because of the abdominal distention and
hepatosplenomegaly.Fig. 1. Clinical features of the patients. A: Case1. Generalized lack of subcutaneous fat, ma
lipodystrophy (B and D), muscular hypertrophy (B), protuberant abdomen and hepatospleno
and crassitude of the penis (B&C).The patient was born at term after an uneventful pregnancy and
delivery. His weight, height and head circumference at birth were
3200 g, 50 cm and 34 cm, respectively. He was the only child of
nonconsanguineous parents. No similar condition was reported in
the family.
On physical examination, his clinical features included gener-
alized lack of subcutaneous fat, muscular hypertrophy of all limbs,
hollow cheeks, low anterior hair line, prominent orbital ridges and
large ears (Fig. 1.A), broad hands and feet with prominent superﬁ-
cial veins and hepatosplenomegaly were noted (Table 1).
Weight, height and head circumference at the age of two
months were 5 kg (25e50 centile), 53 cm (25e50 centile), 39 cm
(50e75 centile), respectively.
Fasting blood sugar (FBS), blood urea nitrogen (BUN), creatinine
(Cr) and electrolytes as well as complete blood count were within
normal limits. The results of serum lipids were triglyceride
3000 mg/dL (normal levels for age and sex, 29e99), cholesterol
550 mg/dL (114e203), high-density lipoprotein (HDL) 28 mg/dL
and low-density lipoprotein (LDL) 78 mg/dL. Liver function and
thyroid function tests were normal.
On imaging, the Z-score of bone mineral density of hip and
lumbar spine was normal. Abdominal ultrasonography revealed
enlargement of the liver (span, 80 mm) and spleen (55 mm). A
3 mm-stone was seen in the lower pole of the left kidney. Random
urine examination for determining the reason of stone revealed the
following results: creatinine 30.5 mg/dL, calcium 6 mg/dL, Ca/Cr
0.19 (normal<0.2), uric acid 46mg/dL, uric acid/Cr 1.5 (normal<1),
oxalate 0.26 mg/dL, oxalate/Cr 0.008 (normal <0.02). Cyanide
nitroprusside test for cystine was negative.
Liver biopsy was performed and revealed marked fatty inﬁl-
tration consistent with the diagnosis of congenital generalized
lipodystrophy (Fig. 1.BeD).
Family 2: The proband (case2) was a 3 months male infant
referred with vomiting, abdominal distention and hepatomegaly.
The parents were ﬁrst cousin and the patient was the only child of
them. Hewas born after an uneventful and full-term pregnancy and
the birth weight was 3450 g. There was no history of similar
condition in the family.rked muscular hypertrophy, hollow cheeks, and broad hands. BeD: Case2. Complete
megaly (black mark for liver border) (B), enlarged hands (B) unusual facial features (B)
Table 1
Clinical features in our patients and previously reported patients with similar
mutations.
Clinical features Case1 Case2 Turkish
patient
Czech
patient
AGPAT2 mutation p.Glu229* p.Glu172Lys p.Glu172Lys p.Glu172Lys
Gender Male Male Male Male
Generalized
lipodystrophy
þ þ þ þ
Muscle hypertrophy þ þ þ þ
Hypercholesterolemia þ þ þ þ
Hypertriglyceridemia þ þ þ þ
Diabetes   þ þ
Raised insulin levels   þ þ
Hepatomegaly þ þ þ þ
Splenomegaly þ  þ 
Acromegaloid features þ þ þ þ
Large ears þ þ þ 
Macrogenitalia þ þ þ 
Inguinal hernia þ   
Nephropathy þ   
Urine bladder calculus þ   
Hydronephrosis  þ  
Gastroesophageal
acid reﬂux
  þ 
Hypertension   þ 
Anemia   þ 
Acanthosis nigricans    þ
Hirsutism    þ
Voice hoarseness    þ
Joint contractures    þ
Cardiomyopathy    þ
Periorbital
hyperpigmentation
   þ
Mental Retardation    
Seizures    
Fig. 2. Histopathology of liver biopsy. Severe steatosis of hepatocytes (>66%), inﬁl-
tration of portal spaces by mononuclear inﬂammatory cells (arrowhead), evidence of
interface hepatitis, ﬁbrous expansion of portal spaces with periportal ﬁbrosis and
occasional portaleportal bridging (long arrow). (hematoxylin and eosin).
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ized lipoatrophy with absence of fat tissue in the face and
extremities (Fig. 1.BeD). An apparent hypertrophy was particularly
present in calf and thigh muscles. The other dysmorphic features
included low anterior hair line, hollow cheeks, prominent orbital
ridges, large ears, prominent veins over large hands and feet and
protuberant abdomen (Table 1). There was no acanthosis nigricans.
The patient had a macropenis with 4 cm in length. The growth
parameters at the age of three months, including height, weight
and head circumference, were 55 cm (50e75 centile), 5 kg (10e
25 centile) and 35 cm (50e75 centile), respectively. Ultrasound
sonography demonstrated hepatomegaly of 11 cm span with
increased echogenicity. Spleen, bladder and left kidney were
normal whereas a mild hydronephrosis and pelvic dilatation
(anteroposterior diameter of 16 mm) were seen in the right kidney
suggesting ureteropelvic junction obstruction (UPJO). On labora-
tory investigation, CBC, liver function tests, BUN, Cr and electrolytes
were normal. Interestingly, the patient did not have elevated blood
sugar (FBS 70 mg/dL) and insulin (7.7 mIU/mL). The homeostatic
model assessment (HOMA-insulin resistance) was calculated from
the formula (insulin [mIU/mL]  glucose [mmol/L]/22.5) and was
1.51. Other laboratory tests included serum cholesterol 221 mg/dL
(114e201), triglyceride levels (non-fasting vs. fasting) 2885 mg/dL
and 1400 mg/dL, respectively (29e99), LDL 79 mg/dL, HDL 30 mg/
dL, VLDL 106 mg/dL, uric acid 7.8 mg/dL (2e6), ammonia 0.9 mg/mL
(0.17e0.8), lactate 47 mg/dL (4.5e20), pyruvate 2 mg/dL (0.3e0.9),
T4 18.1 mg/dL (7.2e14.4), TSH 17.2 mIU/L (1.7e9.1) and serum
calcium 11.3 mg/dL (8.8e11). Creatine phosphokinase (CPK), lactate
dehydrogenase (LDH), serum phosphorus, alkaline phosphatase,
PTH, T3 and 25-hydroxy-vitamin D were within the normal ranges.
A liver biopsy showed steatotic changes andwas consistent with
a diagnosis of non-alcoholic fatty liver disease (NAFLD).On the basis of these ﬁndings, the diagnosis of lipodystrophy
was established and treatment with medium-chain triglyceride
(MCT)-enriched infant formula was started to control
hypertriglyceridemia.
3.2. Genetic investigation
Molecular analysis of AGPAT2 in the proband from family1
(case1) identiﬁed a novel nonsense mutation in exon 6 of the gene.
This mutation (c.685G>T, p.Glu229*) results in premature termi-
nation of the protein in codon 229. The healthy parents of case1
were heterozygous for this novel mutation.
Sequencing of AGPAT2 in the proband of the second family
(case2) revealed a homozygous missense mutation in exon 4;
c.514G>A, p.Glu172Lys. This mutation alters a glutamic acid in
codon 172 to a lysine. Mutation analysis was performed for the
unaffected parents and they were both carries of one copy of
mutation c.514G>A.
4. Discussion
We investigated clinical and molecular features of congenital
generalized lipodystrophy in two new families from Persian pop-
ulation. The clinical diagnosis was made on the basis of character-
istic features of total absence of adipose tissue, apparent muscle
hypertrophy and hyperlipidemia (Table 1).
The histopathological investigation of liver in our patients
revealed steatotic changes consistent with a diagnosis of non-
alcoholic fatty liver disease (Fig. 2). The histopathologic changes
of liver in CGL were investigated previously [20]. The uncharac-
teristic ﬁndings on light microscopy included hepatic steatosis,
presence of lipid droplets in hepatocytes which push the cytoplasm
to the periphery and sometimes cause nuclear indentation, inﬁl-
tration of mononuclear inﬂammatory cells in portal spaces, bile
duct proliferation, interface hepatitis, ﬁbrous expansion of portal
spaces with occasional portaleportal and portalecentral ﬁbrosis,
and cirrhosis. In addition, peroxisomes showed catalase activity in
catalase staining.
Molecular analysis identiﬁed a novel nonsense mutation and
a missense substitution in the AGPAT2 gene responsible for causing
congenital generalized lipodystrophy type 1.
In case1, we identiﬁed a novel homozygous mutation
(c.685G>T) in exon 6 of AGPAT2 gene that is predicted to cause
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codon, removing 50 amino acids from the end of the protein. Since
this mutation is located in the last exon, it is not predicted to result
in nonsense mediated decay. AGPAT2 has two highly conserved
motifs, NHX4D (amino acids 97e103) and EGTR (amino acids 172e
175), shared with other acyltransferases. They have been shown to
be critical for the enzymatic activity of the protein [17,21] and
nonsense or frame shift mutations affecting one or both these
conserved motifs are predicted to be non-functional [22]. Both
these motifs are located outside exon 6 and the novel mutation
identiﬁed by us, c.685G > T, does not affect them. The patient,
case1, demonstrated typical CGL phenotypes, suggesting that the C-
terminal region of 50 amino acids might also have important role in
the protein function. This hypothesis is supported by at least
another report of a nonsense mutation from exon 6, c. 676C>T
(p.226Gln>X), in a Nepali patient from UK [23], that removes 47
amino acids from the protein. This patient had similar features to
case1. In addition, two other mutations, p.L228P and p.252delMRT,
were reported in the far carboxyl-end of the protein that retained
the critical motifs for acyltransferase activity, but had markedly
reduced enzyme activity [9,22].
In case2, the AGPAT2 mutation c.514G>A in exon 4 caused the
missense mutation p.Glu172Lys. The glutamic acid residue is
located within the motif EGTR that is conserved through different
species [17]. It has been shown that this glutamic acid residue is
essential for catalytic function involved in binding of lysophos-
phatidic acid acyltransferase (LPA) [21]. Magre’ et al. [23] reported
two families from Turkey and Czech Republic who had children
affected by CGL and carried homozygous p.Glu172Lys. Both families
had a Turkish ethnic background and based on haplotype analysis,
the authors suggested that they might be related [23]. The Turkish
patient was from a consanguineous family whereas the parents of
the Czech patient were unrelated [23]. Reviewing their clinical
details (Seemanova, E and ’t Hart, L.M., personal communication in
October 2011), most of the ﬁndings were overlapping with that of
our case, whereas some features were distinct (Table 1). None of
our patients had diabetes mellitus and in case2, insulin was
measured at the same time with glucose and was within the
normal range with no insulin resistance (HOMA-IR, normal),
whereas hyperinsulinemia and insulin resistance were observed in
both Turkish and Czech patients. The patient from Turkey had
normal size of ears and penis, whereas our patients and the Czech
patient were born with large ears and genitalia. The distinct ﬁnd-
ings in the Turkish patient included enlarged heart due to hyper-
trophic cardiomyopathy, pathological gastroesophageal acid reﬂux
in pH-metry, moderate hypertension and anemia that was
responsive to iron therapy. He also had limitation in range of
motion of his large joints, particularly of knees and elbows. The
Czech patient had hirsutism, periorbital hyperpigmentation, voice
hoarseness and acanthosis nigricans in neck, axilla and peri-
umbilical region, of which none was present in two other patients.
Hydronephrosis and pelvic dilation were observed only in case2 of
the present report.
Treatment with diet and medium-chain triglyceride (MCT)-
enriched infant formulawas started in both our patients at the time
of diagnosis. Changes in the metabolic parameters of the patients
during treatment have been summarized in Table 2. On the lastTable 2
Changes in the metabolic parameters during treatment.
Patient Case1 Case2
Age (months) 2 m 6 m 12 m 36 m 3 m 5 m 8 m
Fasting glucose (mg/dl) 95 90 90 90 80 74 70
Triglycerides (mg/dl) 3000 1600 625 98 2885 90 73
Total cholesterol (mg/dl) 550 280 200 165 221 112 133follow up of case1, at 3 years of age, the size of his liver and spleen
had returned to normal, whereas the other clinical features of CGL
were present. None of our patients had diabetes/insulin resistance;
however, considering the very young age of our patients, it is
important to note that insulin resistance with diabetes can develop
later in life.
In conclusion, we have identiﬁed two AGPAT2 mutations in two
families with CGL; a novel nonsense mutation (p.Glu229*) and one
missense alteration (p.Glu172Lys). The presence of different clinical
features in CGL patients emphasizes the phenotypic heterogeneity
of this metabolic disorder. This also stresses the importance of
genetic testing in CGL that will have both prognostic and genetic
counseling applications. Moreover, the results of this study support
the idea that besides the two highly conserved motifs, the carboxy
terminal part of AGPAT2 might have an important role in the
activity of the protein and its mutation lead to CGL phenotype. This
is the ﬁrst report of CGL cases from Persian population.
Two mutations from AGPAT2 exon 6 have been previously re-
ported; c. 676C>T (p.226Gln>X, in a Nepali patient from UK) and
c.712C>G (p.238Ala>Gly, in a Czech patient) [23].
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